ABSTRACT
Introduction Tricuspid valve insuciency (TI) is a common condition that is observed in more than 80% of healthy individuals.1 Isolated mild TI is typically well tolerated and patients may remain asymptomatic for many years without specic treatment. However, as TI is frequently secondary to right ventricular dilatation, it is also commonly associated with late stages of le heart valve, myocardial, or pulmonary disease. In these patients, concomitant moderate or severe TI has a signicant impact on functional status and long-term survival. Compared with aortic and mitral valve disease, there is comparatively sparse data from large trials to determine the optimal management strategy for this condition. Surgical therapy is the only established treatment presently available in this dicult patient population. However, in patients with long-standing, symptomatic TI, surgical mortality is high and the decision for surgery is a frequent subject of debate in clinical practice.
